Arbutus Biopharma (ABUS) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$181.7M

Revenue (quarter)

$1.0M

Revenue growth (year over year)

−90.56%

Gross profit (trailing twelve months)

$181.7M

Gross margin

100.00%

Net income (trailing twelve months)

$153.1M

Net income (quarter)

−$5.1M

Net income growth (year over year)

−303.84%

Net margin

84.23%

Return on equity

89.58%

EPS (trailing twelve months)

$0.79

Book value per share

$1.31

P/E (trailing twelve months)

6.56

Price to book

3.88

Debt to assets

5.58%

Payout ratio

—

Dividend yield

—

• Is Arbutus Biopharma (ABUS) profitable?

  Yes. Arbutus Biopharma earned $153.1M in net income over the trailing twelve months, a net margin of 84.23%.

• How much revenue does Arbutus Biopharma (ABUS) make?

  Arbutus Biopharma generated $181.7M in revenue over the trailing twelve months, down 90.56% year over year.

• What is ABUS's P/E ratio?

  Arbutus Biopharma trades at 6.6 times trailing twelve-month earnings, on an EPS of $0.79.

• How do I buy stock in Arbutus Biopharma (ABUS)?

  ABUS trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web dashboard at portal.lighthorse.io, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.